Erratum to: Ann Surg Oncol DOI 10.1245/s10434-014-3486-z
An error occurred in the Methods section, which is corrected here. The first sentence in the second paragraph, under the heading “Neoadjuvant Chemotherapy Regimen,” should read:
Eligible patients were started on an eight-cycle course of 1,000 mg/m2 of gemcitabine and 40 mg/m2 of docetaxel given on days 1 and 8, every 21 days, with intermittent restaging by computed tomographic scan and cancer antigen (CA) 19–9 levels.
The sentence as originally published, “Eligible patients were started on an eight-cycle course of 1,000 mg/m2 of gemcitabine and 80 mg/m2 of docetaxel given on days 1 and 8, every 21 days, with intermittent restaging by computed tomographic scan and cancer antigen (CA) 19–9 levels,” is incorrect.
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found under doi:10.1245/s10434-014-3486-z.
Rights and permissions
About this article
Cite this article
Rose, J.B., Rocha, F.G., Alseidi, A. et al. Erratum to: Extended Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer Demonstrates Promising Postoperative Outcomes and Survival. Ann Surg Oncol 21, 1538 (2014). https://doi.org/10.1245/s10434-014-3640-7
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-014-3640-7